Real‐world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non‐driver gene mutation advanced non‐small cell lung cancer

AIMS: This real‐world study is conducted to evaluate the efficacy and safety of recombinant human endostatin (rh‐endostatin) combined with chemotherapy as first‐line treatment for non‐driver genes mutation non‐small cell lung cancer (NSCLC) patients, and establish evidence‐based optimal regimen for...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhongtai, Zhang, Hui, Zhou, Chunhua, Long, Xiaoyan, Guan, Rui, Yang, Nong, Zhang, Yongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488207/
https://www.ncbi.nlm.nih.gov/pubmed/30762300
http://dx.doi.org/10.1002/cam4.2014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488207/
https://www.ncbi.nlm.nih.gov/pubmed/30762300
http://dx.doi.org/10.1002/cam4.2014

Ejemplares similares